β-Nicotinamide mononucleotide, reduced form (disodium)

β-Nicotinamide mononucleotide, reduced form (disodium)

• CAS Number: 108347-85-9
• UNSPSC Description: β-Nicotinamide mononucleotide, reduced form disodium (β-NMN) is the oxidized form of NAD+ precursor and is a NAD+ enhancer. β-Nicotinamide mononucleotide, reduced form disodium can be reduced to dihydronicotinamide mononucleotide (NMNH). NMNH inhibits glycolysis, TCA cycle, and cell growth[1].
• Target Antigen: Endogenous Metabolite
• Type: Enzyme
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/β-nicotinamide-mononucleotide-reduced-form-disodium.html
• Purity: 98.07
• Solubility: H2O : 125 mg/mL (ultrasonic)
• Smiles: O[C@H]1[C@@H](O)[C@H](N2C=C(CC=C2)C(N)=O)O[C@@H]1COP(O[Na])(O[Na])=O
• Molecular Weight: 380.20
• References & Citations: [1]Liu Y, et al. Reduced Nicotinamide Mononucleotide (NMNH) Potently Enhances NAD+ and Suppresses Glycolysis, the TCA Cycle, and Cell Growth. J Proteome Res. 2021 May 7;20(5):2596-2606.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light, stored under nitrogen)
• Clinical Information: No Development Reported